What the Twins learned over the first half of the season was confirmed the past four days in Kansas City, during four taut games against the defending American League champions.
There are plenty of things the Twins could worry about, as they continue to slip in the standings.
There are no opponents they need fear.
The rise of the Royals as the Twins' primary adversary in the American League Central is, for the Twins, a case of bad timing and ideal circumstance.
The Royals' continued excellence is keeping the Twins out of first place. The Royals' rise to AL power, without the benefit of or reliance upon payroll or power, demonstrates that the path to the World Series is smoother than it has been in decades.
As the Twins welcome back Ervin Santana from a performance-enhancing drug suspension, they can thank steroid testing for a newly leveled playing field.
There always will be players who try to find a pharmaceutical edge, and there always will be those who beat the system. But the elimination of steroids as a constant has also lessened the advantage of big-money and big-market teams, which is why today the American League standings have nothing to do with payroll and everything to do with baseball intelligence and young talent.
Young talent is the new PED — performance-enhancing demographic.